Dose escalation vs. continued doses of paroxetine and maprotiline: A prospective study in depressed out-patients with inadequate treatment response

Acta Psychiatrica Scandinavica

Volumn 95, Issue 4, 1997, Pages 288-296

  Benkert, O ^a   Szegedi, A ^a   Wetzel, H ^a   Staab, H J ^b   Meister, W ^b   Philipp, M ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b SmithKline Beecham Pharma GmbH   (Germany)

Author keywords

Antidepressant drug; Depression; Dose escalation; Maprotiline; Paroxetine

Indexed keywords

MAPROTILINE; PAROXETINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG DOSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0030998015     PISSN: 0001690X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0447.1997.tb09634.x     Document Type: Article

References (24)

1. QUITKIN FM. The importance of dosage in prescribing antidepressants. Br J Psychiatry 1985: 147: 593-597.
2. TOLLEFSON GD. Antidepressant treatment and side-effect considerations. J Clin Psychiatry 1991: 52 (Suppl. 5): 4-13.
3. PERRY PJ, ZEILMANN C, ARNDT S. Tricyclic antidepressant concentrations in plasma: an estimate of their sensitivity and specificity as a predictor of response. J Clin Psychopharmacology 1994: 14: 230-240.
4. MENDELS J, JOHNSTON R, MATTES J, RIESENBERG R. Efficacy and safety of b.i.d. doses of venlafaxine in a dose-response study. Psychopharmacol Bull 1993: 29: 169-174.
5. ALTAMURA AC, MONTGOMERY SA, WERNICKE JF. The evidence for 20 mg fluoxetine as the optimal dose in the treatment of depression. Br J Psychiatry 1988: 153 (Suppl. 3): 109-112.
6. DORNSEIF BE, WERNICKE JF, DUNLOP SR, POTVIN JH. Effect of dose escalation after low-dose fluoxetine therapy. Presentation at New Clinical Drug Evaluation Unit, June 1988.
7. DUNNER DL, DUNBAR MC. Optimal dose regimen for paroxetine. J Clin Psychiatry 1992: 53 (Suppl. 2): 21-26.
8. JENNER PN Paroxetine: an overview of dosage, tolerability and safety. Int Clin Psychopharmacology 1992: 6 (Suppl. 4): 69-80.
9. HEBENSTREIT GF, FELLERER K, ZÖCHLING R, ZENTZ A, DUNBAR GC. A pharmacokinetic dose titration study in adult and elderly depressed patients. Acta Psychiatr Scand 1990: 80 (Suppl. 350): 81-84.
10. BIGNAMINI A, RAPISARDA V. A double-blind multicentre study of paroxetine and amitriptyline in depressed outpatients. Int Clin Psychopharmacology 1992: 6 (Suppl. 4): 37-23.
11. TASKER TCG, KAYE CM, ZUSSMAN BD, LINK CGG. Paroxetine plasma levels: lack of correlation with efficacy or adverse events. Acta Psychiatr Scand 1990: 80 (Suppl. 350): 152-155.
12. DECHANT KL, CLISSOLD SP. Paroxetine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in depressive illness. Drugs 1991: 41 (Suppl. 2): 225-253.
13. LEONARD BE. The comparative pharmacology of new antidepressants. J Clin Psychiatry 1993: 54 (Suppl. 8): 3-15.
14. SCHWEIZER E, RICKELS K, AMSTERDAM JD, FOX I, PUZZUOLI G, WEISE C. What constitutes an adequate antidepressant trial for fluoxetine? J Clin Psychiatry 1990: 51: 8-11.
15. THOMPSON C, LANE R Sertraline 50 mg: optimal daily dose in depression (abstract). Neuropsychopharmacology 1994: 10: 222S.
16. STUPPAECK CH, GERETSEGGER C, WHITWORTH AB et al. A multicenter double-blind trial of paroxetine versus amitriptyline in depressed inpatients. J Clin Psychopharmacology 1994: 14: 241-246.
17. Fluoxetine Bulimia Nervosa Collaborative Study Group (FBNCSG). Fluoxetine in the treatment of bulimia nervosa. Arch Gen Psychiatry 1992: 49: 139-147.
18. TOLLEFSON GD, RAMPEY AH, POTVIN JH et al. A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder. Arch Gen Psychiatry 1994: 51: 559-567.
19. FAVA M, RAPPE SM, PAVA JA, NIERENBERG AA, ALPERT JE, ROSENBAUM JF. Relapse in patients on long-term fluoxetine treatment: response to increased fluoxetine dose. J Clin Psychiatry 1995: 56: 52-55.
20. PRESKORN SH. Pharmacokinetics of antidepressants: why and how they are relevant to treatment. J Clin Psychiatry 1993: 54 (Suppl. 9): 14-34.
21. KASPER S, DÖTSCH M, KICK H, VIEIRA A, MÖLLER HJ. Plasma concentrations of fluvoxamine and maprotiline in major depression: implications for therapeutic efficacy and side-effects. Eur Neuropsychopharmacology 1993: 3: 13-21.
22. FINDER RM. Maprotiline: a review of its pharmacological properties and therapeutic efficacy in mental depressive states. Drugs 1977: 13: 321.
23. DILLIER N. Worldwide clinical experience with Ludiomil. Activ Nerv Sup (CS) 1982: 24: 40.
24. ELKIN I, SHEA T, WATKINS JT et al. National Institute of Mental Health Treatment of Depression Collaborative Research Program - general effectiveness of treatments. Arch Gen Psychiatry 1989: 46: 971-982.